/ Lupin Receives FDA Nod For Generic Evoxac Capsules ~ Ways2Capital|Stock Tips|Stock Market Tips|Intraday Stock Tips|Stock Trading Tips|NSE BSE Tips

Monday, 2 January 2017

Pharma Major Lupin Limited has received final approval for its Cevimeline Hydrochloride Capsules, 30 mg from the United States Food and Drug Administration (FDA) to market a generic version of Daiichi Sankyo Inc's Evoxac Capsules, 30 mg. Lupin shall commence promoting the product  shortly.

Lupin's Cevimeline Hydrochloride Capsules, 30 mg are the AB rated generic equivalent of Daiichi Sankyo Inc's Evoxac Capsules, 30 mg. Cevimeline Hydrochloride Capsules, 30 mg are indicated for the treatment of symptoms of dry mouth in patients with Sjiigren's Syndrome. Evoxac Capsules had US sales of USD 40.8 million (IMS MAT September 2016).
Lupin Ltd is currently trading at Rs 1499.15, up by Rs 15.45 or 1.04% from its previous closing of Rs 1483.7 on the BSE. The scrip opened at Rs 1495.9 and has touched a high and low of Rs 1508.55 and Rs 1477.7 respectively. So far 208746(NSE+BSE) shares were traded on the counter. The current market cap of the company is Rs 66979.52 crore.

The BSE group 'A' stock of face value Rs 2 has touched a 52 week high of Rs 1911.55 on 09-Feb-2016 and a 52 week low of Rs 1294.05 on 29-Mar-2016. Last one week high and low of the scrip stood at Rs 1490 and Rs 1399 respectively.

The promoters holding in the company stood at 46.74 % while Institutions and Non-Institutions held 41.85 % and 11.41 % respectively. The stock is currently trading above its 200 DMA.

For Quick Trial – 8962000225 ✔
or mail us here: info@ways2capital.com
✆ - 0731-6626222 | Toll Free - 1800-3010-2007
Give a Missed Call for Free Trial - 09699997717